CMND-100 is Clearmind’s proprietary MEAI-based oral drug candidate, developed as a potential breakthrough treatment for AUD. Unlike traditional treatment methods, CMND-100 is designed to offer a novel ...

Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development ...

Detailed price information for Spectral Medical Inc (EDT-T) from The Globe and Mail including charting and trades.

Topline results expected to be released in August 2025Company to host Corporate Update Call on May 15, 2025 TORONTO, April 16, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc.

Stéphane Piat, Chief Executive Officer of CARMAT, stated: "The authorization to initiate the second cohort of our Early Feasibility Study (EFS) in the United States, received from the FDA, marks a ...

This clearance marks a significant advancement in glaucoma care, especially for earlier stages of the disease and across a wide spectrum of ...

Regeneron (REGN) announces FDA review of sBLA for Eylea HD to treat macular edema and expand dosing. Read more here.

Qure (QURE) stock surges 39% as FDA grants Breakthrough Therapy designation for AMT-130, a gene therapy for Huntington’s disease. Read more here.

President Donald Trump's approval ratings are a measure of how Americans really feel about his job performance on any given day, often times driven by his handling of the issues at hand.